Press Releases

• Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
  Jun 1, 2022 14:00 (CEST) Regulatory item
• Annual General Meeting of Active Biotech AB
  May 19, 2022 17:00 (CEST) Regulatory item
• FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
  May 18, 2022 15:00 (CEST) Regulatory item
• Annual Report 2021 Active Biotech AB (publ)
  Apr 28, 2022 09:40 (CEST) Regulatory item
• Active Biotech strengthens the patent protection for laquinimod in eye disorders
  Apr 26, 2022 08:30 (CEST) Regulatory item